Search results
Results from the WOW.Com Content Network
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. Shares of newly public AMRX began trading on the NYSE on May 7, 2018. [9] Concurrent with the Impax merger, Amneal acquired Gemini Laboratories for $117 million, including Unithroid, Gemini's lead product for treating hypothyroidism. [10]
Impax Laboratories (NAS: IPXL) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter ...
Shares of Impax Laboratories spiraled down more than 25% today after the company reported that the FDA continues to have concerns with one of its manufacturing facilities. This issue has already ...
Impax Laboratories (NAS: IPXL) reported earnings on May 1. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q1), Impax Laboratories beat expectations ...
Impax Laboratories (NAS: IPXL) reported earnings yesterday. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended March 31 (Q1), Impax Laboratories whiffed on revenues ...
Impax Laboratories (NAS: IPXL) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter ...
Impax Laboratories (NAS: IPXL) is expected to report Q4 earnings on Feb. 25. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter ...
The company acquired the US marketing rights to Daraprim from Impax Laboratories in August 2015. [8] In September 2015, Turing raised the price of Daraprim from $13.50 to $750 a tablet. This increase prompted widespread criticism of the company from many quarters, including the pharmaceutical industry itself. [9]